Why the study?
Frequent postoperative complications and restrictions associated with surgical septal myectomy provide rationale for improving current treatments and exploring new pharmacological approaches in hypertrophic cardiomyopathy.
This review highlights current surgical treatments for HCM and the promising role of mavacamten as an emerging pharmacological therapy.
Hypertrophic cardiomyopathy (HCM) is a genetically determined disease with a high prevalence and manifestation at the age of 30–40 years. Currently available most effective treatments are extended myectomy and Morrow septal myectomy. However, the frequent occurrence of postoperative complications and restrictions to the use of these methods in certain groups of patients provides rationale for the improvement of the existing treatment methods and search for new pharmacological approaches. One of the most promising areas of conservative therapy is the study of a specific small-molecule allosteric inhibitor of myosinadenosine triphosphatase (mavacamten). Clinical studies of the efficacy and safety of this drug continue to this day, and if they are successfully completed, the drug may be included in the pharmacotherapy protocol for HCM.
No takes yet. Share an insight, caveat, or question.
Zakharyan et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: